CRDL
Cardiol Therapeutics Inc-A
NASDAQ · Pharmaceuticals
$0.99
+0.03 (+3.63%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.47M | 20.00M | 18.14M |
| Net Income | 5.10M | 5.20M | 4.96M |
| EPS | — | — | — |
| Profit Margin | 23.8% | 26.0% | 27.3% |
| Rev Growth | +3.9% | -4.2% | -9.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 64.11M | 70.42M | 60.03M |
| Total Equity | 55.27M | 55.09M | 60.24M |
| D/E Ratio | 1.16 | 1.28 | 1.00 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 10.24M | 10.30M | 9.42M |
| Free Cash Flow | 5.58M | 6.38M | 6.16M |